Sun Pharmaceutical Industries Ltd

Sun Pharmaceutical Industries Ltd, a stalwart in the Pharmaceuticals & Biotechnology sector, continues to demonstrate resilience and strategic significance as a Nifty 50 constituent. Recent market movements and institutional holding trends underscore the stock’s pivotal role within India’s benchmark index, reflecting both sectoral strength and evolving investor sentiment.

A price-to-earnings ratio of 35.44 against an industry average of 36.93 indicates that Sun Pharmaceutical Industries Ltd trades at a slight discount to its sector peers. Previously rated Buy by MarketsMOJO, the stock’s rating was reassessed on 3 September 2026. While the one-year return of 13.43% comfortably outpaces the Sensex’s decline of 10.29%, the shorter-term performance reveals a more nuanced picture.

A price-to-earnings ratio of 35.2 against an industry average of 36.44 indicates that Sun Pharmaceutical Industries Ltd trades at a slight discount to its sector peers. Previously rated Buy by MarketsMOJO, the company’s rating was reassessed on 3 September 2026. While the one-year return of 14.57% comfortably outpaces the Sensex’s decline of 10.03%, the three-month performance shows a more modest 1.99% gain, signalling a shift in momentum over recent months.

A price-to-earnings ratio of 34.85 against an industry average of 36.52 indicates a modest valuation discount for Sun Pharmaceutical Industries Ltd. Previously rated Buy by MarketsMOJO, the stock’s rating was reassessed on 3 September 2026. While the one-year return of 14.78% comfortably outpaces the Sensex’s decline of 9.71%, the shorter-term performance reveals a more nuanced picture with mixed momentum across recent months.

A price-to-earnings ratio of 34.98 against an industry average of 37.05 reveals a modest valuation discount for Sun Pharmaceutical Industries Ltd. Previously rated Buy by MarketsMOJO, the stock’s rating was reassessed on 3 September 2026. While the one-year return comfortably outpaces the Sensex, recent months have shown a more nuanced momentum picture, underscoring the importance of timeframe in analysing this large-cap pharmaceutical giant.

A price-to-earnings ratio of 35.4 against an industry average of 37.05 indicates a modest valuation discount for Sun Pharmaceutical Industries Ltd. Previously rated Buy by MarketsMOJO, the stock’s rating was reassessed on 03 Sep 2026. While the one-year return of 14.72% comfortably outpaces the Sensex’s decline of 8.94%, the recent four-day losing streak and underperformance over shorter intervals suggest a nuanced momentum picture.

A price-to-earnings ratio of 35.48 against an industry average of 37.21 reveals a modest valuation discount for Sun Pharmaceutical Industries Ltd. Previously rated Buy by MarketsMOJO, the stock’s rating was reassessed on 3 September 2026. While the one-year return of 17.03% comfortably outpaces the Sensex’s decline of 8.03%, recent three-month gains of 4.36% suggest a shift in momentum that merits closer examination.

A price-to-earnings ratio of 35.72 against an industry average of 37.46 marks a modest valuation discount for Sun Pharmaceutical Industries Ltd. Previously rated Buy by MarketsMOJO, the stock’s rating was reassessed on 3 September 2026. While the one-year return of 18.78% comfortably outpaces the Sensex’s negative 7.46%, the recent three-month performance of 6.47% versus the Sensex’s 1.53% suggests a nuanced momentum shift worth closer examination.

A price-to-earnings ratio of 36.08 against an industry average of 37.22 indicates that Sun Pharmaceutical Industries Ltd trades at a slight discount to its sector peers. Previously rated Buy by MarketsMOJO, the company’s rating was reassessed on 03 Sep 2026. While the one-year return of 19.31% comfortably outpaces the Sensex’s negative 6.17%, the short-term momentum shows a more nuanced picture with recent underperformance — what is the current rating?

Sun Pharmaceutical Industries Ltd, a stalwart in the Pharmaceuticals & Biotechnology sector and a key constituent of the Nifty 50 index, continues to demonstrate resilience despite recent short-term headwinds. With a market capitalisation exceeding ₹4.55 lakh crores and a recent Mojo Grade downgrade from Buy to Hold, the stock’s performance and institutional interest remain pivotal for investors tracking benchmark indices and sectoral trends.

Sun Pharmaceutical Industries Ltd experienced a nuanced week with its stock price declining marginally by 1.10% to close at Rs.1,899.00 on 4 September 2026, slightly outperforming the Sensex which fell 1.11% over the same period. The week was marked by a shift in technical momentum from bullish to mildly bullish, increased call option activity ahead of the September expiry, and a downgrade in the company’s Mojo Grade from Buy to Hold, reflecting a more cautious market stance amid mixed fundamental and technical signals.

Sun Pharmaceutical Industries Ltd continues to assert its prominence within the Nifty 50 index, bolstered by a recent upgrade in its Mojo Grade to 'Buy' and sustained outperformance against the Sensex over multiple time horizons. Despite a modest dip of 0.40% on 3 September 2026, the stock's large-cap stature and robust institutional interest underscore its critical role in the Pharmaceuticals & Biotechnology sector and the broader benchmark landscape.

Sun Pharmaceutical Industries Ltd continues to solidify its stature within the Nifty 50 index, reflecting robust institutional interest and outperforming key benchmarks despite recent short-term volatility. The company’s upgraded rating and sustained large-cap status underscore its pivotal role in India’s pharmaceuticals and biotechnology sector.